Esperion Therapeutics, Inc. Profile Avatar - Palmy Investing

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoi…

Drug Manufacturers - Specialty & Generic
US, Ann Arbor [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Esperion Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Esperion Therapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Esperion Therapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of ESPR's Analysis
CIK: 1434868 CUSIP: 29664W105 ISIN: US29664W1053 LEI: - UEI: -
Secondary Listings
ESPR has no secondary listings inside our databases.